公开(公告)号：US20180353561A1

公开(公告)日：2018-12-13

申请号：US15573207

申请日：2016-05-13

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Sei-Ryang OH ,  Kyung Seop AHN ,  Su Ui LEE ,  Hyung Won RYU ,  Doo-Young KIM ,  Hyeong Kyu LEE ,  Ok-Kyoung KWON ,  Jung Hee KIM ,  Hyun-Jun LEE ,  In-Sik SHIN

IPC: A61K36/575 ,  A61K31/34 ,  A61K31/357 ,  A61P35/00 ,  A61P9/00

CPC classification number: A61K36/575 ,  A61K9/0019 ,  A61K9/0095 ,  A61K31/34 ,  A61K31/357 ,  A61K31/36 ,  A61K47/38 ,  A61P9/00 ,  A61P11/00 ,  A61P35/00

Abstract: A pharmaceutical composition includes any of an extract of Magnoliae flos, a fraction or an active fraction obtained by fractionation thereof with an organic solvent, and a compound separated therefrom as an active ingredient. The extract of Magnoliae flos, the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom inhibits the expression of MUC5AC induced by TNF-α and the promoter activity in human lung cancer mucosal cells (H292), reduces the number of inflammatory cells in the bronchoalveolar lavage fluid of the chronic obstructive pulmonary disease mouse model, inhibits the production of reactive oxygen species, and reduces the cytokines; and therefore are effective in preventing or treating chronic obstructive pulmonary disease.

公开(公告)号：US20180105548A1

公开(公告)日：2018-04-19

申请号：US15511014

申请日：2016-06-15

Applicant: YUNGJIN PHARMACEUTICAL CO., LTD ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Yongnam LEE ,  Ji-seok YOO ,  Dae-hee SHIN ,  Byung-hwan RYOO ,  Sei-ryang OH ,  Kyung-seop AHN ,  Hyeongkyu LEE ,  Su Ui LEE ,  Hyuk-hwan SONG ,  Hyung Won RYU

IPC: C07H17/04 ,  A61P37/08 ,  A61P29/00 ,  A61P11/06 ,  A61P11/00 ,  A23L33/105 ,  A23L33/00

CPC classification number: C07H17/04 ,  A23L33/105 ,  A23L33/30 ,  A23V2002/00 ,  A61K9/0019 ,  A61K9/0095 ,  A61K9/2018 ,  A61K9/2059 ,  A61K36/80 ,  A61K47/02 ,  A61P11/00 ,  A61P11/06 ,  A61P29/00 ,  A61P37/08 ,  C07H17/08

Abstract: (1aS,1bS,2S,4S,5aR,6S,6aS)-1a-(hydroxymethyl)-4-methoxy-2-(((2S,3R,5S5,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)octahydrooxireno[2′,3′:4,5]cyclopenta[1,2-c]pyran-6-yl 4-hydroxybenzoate}, the isomer thereof, the pharmaceutically acceptable salt or solvates thereof, a composition comprising the same as an active ingredient for treating allergic disease, inflammatory disease, asthma or chronic obstructive pulmonary disease (COPD) and the use thereof.

公开(公告)号：US20160199339A1

公开(公告)日：2016-07-14

申请号：US14912920

申请日：2014-08-19

Applicant: ENZYCHEM LIFESCIENCES CORPORATION ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Sei-Ryang OH ,  Kyung Seop AHN ,  Su Ui LEE ,  In Sik SHIN ,  Na-Rae SHIN ,  Tae-Suk LEE ,  JongKoo KANG ,  Young-Sik JUNG ,  Yong-Hae HAN ,  Ki Young SOHN

IPC: A61K31/231

CPC classification number: A61K31/231 ,  A23K20/00 ,  A23L33/40 ,  A23V2002/00 ,  A61K35/32

Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.

Abstract translation: 本发明涉及一种含有单乙酰基二酰基甘油化合物作为预防或治疗哮喘的活性成分的药物组合物，以及用于预防或治疗哮喘的功能保健食品组合物。 本发明的单乙酰基二酰基甘油化合物抑制作为小鼠T细胞淋巴瘤细胞的EL-4细胞中IL-4的表达，降低哮喘诱发的动物模型中气道的超敏反应，并抑制炎症细胞浸润到支气管 管。 此外，本发明的化合物抑制血清和支气管肺泡灌洗液中IgE的产生，具有抑制肺中Th2细胞因子（IL-4，IL-5和IL-13）表达的优异效果 从而克服目前使用的哮喘治疗剂的副作用，没有毒性，表现出优异的治疗效果，因此可用作预防，治疗和缓解哮喘的组合物。

公开(公告)号：US20240254155A1

公开(公告)日：2024-08-01

申请号：US18564361

申请日：2022-05-04

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Hyung Won RYU ,  Su Ui LEE ,  Sei-Ryang OH ,  Jae-Won LEE ,  Doo-Young KIM ,  Hyun-Jae JANG ,  Mun-Ock KIM ,  Seong Hun JEONG

IPC: C07H15/256 ,  A61K31/704 ,  A61K36/21 ,  A61P11/06 ,  A61P29/00 ,  C07H1/08

CPC classification number: C07H15/256 ,  A61K31/704 ,  A61K36/21 ,  A61P11/06 ,  A61P29/00 ,  C07H1/08 ,  A61K2236/33 ,  A61K2236/55

Abstract: The present invention relates to a novel compound isolated from spinach, and a composition comprising same for preventing or treating inflammatory diseases, and, more particularly, to a novel medicagenic acid glycoside compound isolated from spinach, a preparation method therefor, and a composition comprising same for preventing or treating inflammatory diseases.

公开(公告)号：US20230364170A1

公开(公告)日：2023-11-16

申请号：US18024604

申请日：2021-08-18

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Su Ui LEE ,  Hyung Won RYU ,  Mun Ock KIM ,  Sei Ryang OH ,  Doo Young KIM ,  Hyun Jae JANG

IPC: A61K36/258 ,  A61K31/585 ,  A61K36/38 ,  A61K31/194 ,  A61P3/08 ,  A61P3/04

CPC classification number: A61K36/258 ,  A61K31/585 ,  A61K36/38 ,  A61K31/194 ,  A61P3/08 ,  A61P3/04

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating obesity or diabetes, and to a food composition and feed composition for preventing or alleviating obesity or diabetes, comprising as an active ingredient, an Acanthopanax extract, a garcinia cambogia extract, or compounds isolated therefrom. The composition has synergistic antidiabetic and antiobesity activity compared to that of using only an Acanthopanax extract, a garcinia cambogia extract, or compounds isolated therefrom. Therefore, it is possible to reduce the possibility of any side effects that may be caused by an overdose of or long-term administration of the garcinia cambogia extract and a substance isolated therefrom, and thus the composition can be very effectively utilized in the development of a therapeutic agent for diabetes or obesity.

公开(公告)号：US20240261356A1

公开(公告)日：2024-08-08

申请号：US18290222

申请日：2022-05-11

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Su Ui LEE ,  Mun-Ock KIM ,  Hyung Won RYU ,  Sei-Ryang OH ,  Doo-Young KIM ,  Jae-Won LEE

IPC: A61K36/254 ,  A61K31/191 ,  A61K31/365 ,  A61K36/38 ,  A61P1/16

CPC classification number: A61K36/254 ,  A61K31/191 ,  A61K31/365 ,  A61K36/38 ,  A61P1/16 ,  A61K2236/39

Abstract: The present invention relates to a composition containing extracts from Garcinia cambogia and Acanthopanax for prevention or treatment of liver diseases and, more specifically, to a composition for prevention or treatment of liver disease, the composition containing, as active ingredients, (i) a Garcinia cambogia extract, hydroxycitric acid (HCA), or a derivative of hydroxycitric acid; and (ii) an Acanthopanax extract, Chiisanogenin, or a derivative of Chiisanogenin.

公开(公告)号：US20170217982A1

公开(公告)日：2017-08-03

申请号：US15328056

申请日：2015-07-22

Applicant: YUNGJIN PHARMACEUTICAL CO., LTD ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Yongnam LEE ,  Ji-seok YOO ,  Dae-hee SHIN ,  Byung-hwan RYOO ,  Sei-ryang OH ,  Kyung-seop AHN ,  Hyeongkyu LEE ,  Su Ui LEE ,  Hyuk-hwan SONG ,  In Sik SHIN ,  Hyung Won RYU

IPC: C07D493/08 ,  A61K36/68 ,  A23L2/52 ,  A23L33/155 ,  A23L33/15 ,  A23L33/16 ,  A61K31/357 ,  A23L33/105

CPC classification number: C07D493/08 ,  A23L2/52 ,  A23L33/105 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23V2002/00 ,  A61K31/357 ,  A61K36/68 ,  A61K36/80 ,  C07H17/04

Abstract: A compound (3R,5S,5aS,6R,7S,8R,8aS)-8-chloro-8a-hydroxy-5-(2-hydroxy acetoxy) hexahydro-1H-3,6-methanocyclopenta[e][1,3]dioxepin-7-yl 3,4-dihydroxybenzoate (KS534), the isomer thereof, the pharmaceutically acceptable salt or solvates thereof, a composition comprising the same as an active ingredient for treating allergic disease, inflammatory disease, asthma or chronic obstructive pulmonary disease (COPD)

公开(公告)号：US20170042854A1

公开(公告)日：2017-02-16

申请号：US14912765

申请日：2014-08-19

Applicant: ENZYCHEM LIFESCIENCES CORPORATION ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Sei-Ryang OH ,  Kyung Seop AHN ,  Su Ui LEE ,  In Sik SHIN ,  Ok-Kyoung KWON ,  Seung Hyung KIM ,  Chan Mi CHUN ,  Tae-Suk LEE ,  Yong-Hae HAN ,  Ki Young SOHN ,  JongKoo KANG ,  Hye Kyung KIM

IPC: A61K31/231

CPC classification number: A61K31/231

Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating chronic obstructive pulmonary diseases, and a functional health food composition for treating or preventing chronic obstructive pulmonary diseases. The monoacetyldiacylglycerol compound of the present invention inhibits the IL-4 expression in EL-4 cells and inhibits the infiltration of inflammatory cells into the bronchial tube in an animal model. In addition, the compounds of the present invention have an excellent effect of inhibiting the expression of CXCL-1, TNF-α, or MIP-2, thereby overcoming side effects of the currently used therapeutic agents for chronic obstructive pulmonary diseases, having no toxicity, and exhibiting a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating chronic obstructive pulmonary diseases.

Abstract translation: 本发明涉及含有单乙酰二酰基甘油化合物作为预防或治疗慢性阻塞性肺疾病的活性成分的药物组合物，以及用于治疗或预防慢性阻塞性肺疾病的功能保健食品组合物。 本发明的单乙酰基二酰基甘油化合物抑制EL-4细胞中的IL-4表达，并且在动物模型中抑制炎性细胞浸润到支气管中。 此外，本发明的化合物具有抑制CXCL-1，TNF-α或MIP-2的表达的优异效果，从而克服了目前使用的治疗剂对于无毒性的慢性阻塞性肺疾病的副作用 并且具有优异的治疗效果，因此可用作预防，治疗和缓解慢性阻塞性肺疾病的组合物。